Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines net income 2017–2026What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Revolution Medicines lost 407.46M USD in Q3 FY2026, the three months to 30 September 2026, against a loss of 305.21M USD on the same quarter a year before. Revolution Medicines made a net loss of 1.13B USD in fiscal year 2025, against a loss of 600.09M USD on the year before.
Last updated 8 Nov 2026 · Next report 24 Feb 2027
Net income
Net income Net margin
| Fiscal year | Period ending | Net income | Growth | Net margin | Revenue |
|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | -1.87B | — | — | — |
| FY2025 | 31 Dec 2025 | -1.13B | — | — | 0.00 |
| FY2024 | 31 Dec 2024 | -600.09M | — | — | 0.00 |
| FY2023 | 31 Dec 2023 | -436.37M | — | -3,768.28% | 11.58M |
| FY2022 | 31 Dec 2022 | -248.71M | — | -702.95% | 35.38M |
| FY2021 | 31 Dec 2021 | -187.09M | — | -636.58% | 29.39M |
| FY2020 | 31 Dec 2020 | -108.16M | — | -251.63% | 42.98M |
| FY2019 | 31 Dec 2019 | -47.66M | — | -95.25% | 50.04M |
| FY2018 | 31 Dec 2018 | -41.79M | — | -207.24% | 20.17M |
| FY2017 | 31 Dec 2017 | -31.13M | — | — | 0.00 |
| Quarter | Period ending | Net income | Growth on a year before | Net margin | Revenue |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | -407.46M | — | -206.25% | 197.56M |
| Q2 FY2026 | 30 Jun 2026 | -644.37M | — | — | 0.00 |
| Q1 FY2026 | 31 Mar 2026 | -453.82M | — | — | 0.00 |
| Q4 FY2025 | 31 Dec 2025 | -364.89M | — | — | 0.00 |
| Q3 FY2025 | 30 Sept 2025 | -305.21M | — | — | 0.00 |
| Q2 FY2025 | 30 Jun 2025 | -247.79M | — | — | 0.00 |
| Q1 FY2025 | 31 Mar 2025 | -213.42M | — | — | 0.00 |
| Q4 FY2024 | 31 Dec 2024 | -194.57M | — | — | 0.00 |
| Q3 FY2024 | 30 Sept 2024 | -156.29M | — | — | 0.00 |
| Q2 FY2024 | 30 Jun 2024 | -133.23M | — | — | 0.00 |
| Q1 FY2024 | 31 Mar 2024 | -116.00M | — | — | 0.00 |
| Q4 FY2023 | 31 Dec 2023 | -161.54M | — | -21,770.49% | 742.00K |
| Q3 FY2023 | 30 Sept 2023 | -108.43M | — | — | 0.00 |
| Q2 FY2023 | 30 Jun 2023 | -98.30M | — | -2,570.55% | 3.82M |
| Q1 FY2023 | 31 Mar 2023 | -68.10M | — | -970.89% | 7.01M |
| Q4 FY2022 | 31 Dec 2022 | -56.51M | — | -368.60% | 15.33M |
| Q3 FY2022 | 30 Sept 2022 | -73.33M | — | -2,185.01% | 3.36M |
| Q2 FY2022 | 30 Jun 2022 | -61.22M | — | -671.59% | 9.12M |
| Q1 FY2022 | 31 Mar 2022 | -57.65M | — | -760.72% | 7.58M |
| Q4 FY2021 | 31 Dec 2021 | -52.68M | — | -556.83% | 9.46M |
| Q3 FY2021 | 30 Sept 2021 | -52.94M | — | -4,808.36% | 1.10M |
| Q2 FY2021 | 30 Jun 2021 | -44.30M | — | -509.30% | 8.70M |
| Q1 FY2021 | 31 Mar 2021 | -37.18M | — | -366.95% | 10.13M |
| Q4 FY2020 | 31 Dec 2020 | -34.20M | — | -390.86% | 8.75M |
| Q3 FY2020 | 30 Sept 2020 | -27.22M | — | -215.00% | 12.66M |
| Q2 FY2020 | 30 Jun 2020 | -27.22M | — | -271.47% | 10.03M |
| Q1 FY2020 | 31 Mar 2020 | -19.52M | — | -169.05% | 11.55M |
| Q4 FY2019 | 31 Dec 2019 | -14.60M | — | -120.75% | 12.09M |
| Q3 FY2019 | 30 Sept 2019 | -12.82M | — | -102.49% | 12.51M |
| Q2 FY2019 | 30 Jun 2019 | -10.12M | — | -82.40% | 12.28M |
| Q1 FY2019 | 31 Mar 2019 | -10.13M | — | -76.95% | 13.17M |
| Q4 FY2018 | 31 Dec 2018 | -11.34M | — | -109.59% | 10.35M |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Income statement
Common questions about Revolution Medicines's profit
Source: Financial Modeling PrepVerified against SEC filings